Ventyx Biosciences, Inc.
General ticker "VTYX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $173.0M (TTM average)
Ventyx Biosciences, Inc. follows the US Stock Market performance with the rate: 42.9%.
Estimated limits based on current volatility of 6.9%: low 7.65$, high 8.79$
Factors to consider:
- Total employees count: 79 (0.0%) as of 2024
- Top business risk factors: Product development risks, Insufficient funding, Economic downturns and volatility, Cybersecurity threats, Strategic risks and growth management
- Current price 120.4% above estimated high
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.09$, 3.63$]
- 2025-12-31 to 2026-12-31 estimated range: [1.32$, 4.22$]
Financial Metrics affecting the VTYX estimates:
- Positive: with PPE of -1.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -83.62 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 91.86 > 63.39
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Industry earnings per price (median), % of -16.34 <= 0
Short-term VTYX quotes
Long-term VTYX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $113.14MM | $207.99MM | $148.45MM |
| Operating Income | $-113.14MM | $-207.99MM | $-148.45MM |
| Non-Operating Income | $4.71MM | $15.03MM | $13.33MM |
| R&D Expense | $87.74MM | $175.77MM | $117.00MM |
| Income(Loss) | $-108.43MM | $-192.96MM | $-135.12MM |
| Profit(Loss)* | $-108.43MM | $-192.96MM | $-135.12MM |
| Stockholders Equity | $353.89MM | $243.92MM | $254.04MM |
| Assets | $371.40MM | $277.69MM | $276.56MM |
| Operating Cash Flow | $-98.77MM | $-166.52MM | $-130.87MM |
| Capital expenditure | $0.28MM | $0.51MM | $0.24MM |
| Investing Cash Flow | $-74.93MM | $100.94MM | $-15.51MM |
| Financing Cash Flow | $167.77MM | $53.33MM | $122.11MM |
| Earnings Per Share** | $-2.07 | $-3.30 | $-1.97 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.